Liraglutide biosimilar (HEC)
利拉鲁肽生物类似药（东阳光）
Report date: 2022/10/25 16:00:16
Base Information
Drug NameLiraglutide biosimilar (HEC)
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesGuangdong Dongyangguang Pharmaceutical Co LtdGuangdong Dongyang Biological Agent Co Ltd
China Registration ClassN/A
Develop Information
Active CompaniesGuangdong Dongyangguang Pharmaceutical Co LtdGuangdong Dongyang Biological Agent Co Ltd
Inactive CompaniesSunshine Lake Pharma Co Ltd
Active Indications
Inactive IndicationsN/A
Other Information
ATC CodeN/A
Related LinksN/A